In-vitro Diagnostics Market is expected to reach US$ 218.73 Billion by 2034

Reagents and Kits by Product Segment Drives In-Vitro Diagnostics Market Growth

According to our new research study named "In-vitro Diagnostics Market Forecast to 2031 – Global Analysis – by Product, Technology, Application, Usability, Site of Testing, Specimen, and End User," the market was valued at US$ 112.04 Billion in 2025 and is projected to reach US$ 218.73 Billion by 2034; it is expected to register a CAGR of 7.8% during 2026–2034 The rising prevalence of chronic and infectious diseases, as well as technological advancements, and increasing adoption of self-administration and growing healthcare awareness and screening programs are driving the in-vitro diagnostics market size. However, the high cost of advanced diagnostics and stringent regulatory compliance, and skilled workforce shortage hinder the In-vitro diagnostic market growth. The expansion in emerging markets and home-based diagnostic solutions is projected to bring new in-vitro diagnostic market trends in the coming years.

According to the World Health Organization (WHO), noncommunicable diseases (NCDs) such as cardiovascular disease, cancer, diabetes, and chronic respiratory disease caused at least 43 million deaths in 2021, equating to roughly 75% of all non-pandemic deaths worldwide, with cardiovascular diseases alone accounting for nearly 19 million deaths that year.

In-vitro Diagnostic Market, by Region, 2024 (%)

Diabetes, which requires regular biochemical and molecular tests for monitoring and management, has escalated sharply; the number of people living with diabetes globally increased from 200 million in 1990 to 830 million in 2022, with a more rapid rise in low and middle-income countries. 

WHO estimated that in 2022, approximately 254 million people were living with chronic hepatitis B and 50 million with hepatitis C worldwide, contributing to significant morbidity and about 1.3 million deaths annually from liver disease and related complications. 

These global disease burdens translate into increased utilization of IVD products such as serology tests, molecular assays, and biomarkers for early disease detection, monitoring, and screening, particularly for viral hepatitis, diabetes, and cardiovascular disorders.

Country-specific health data highlights this trend. In India, hypertension and diabetes account for a majority of the disease burden, with hypertension present in 32% and diabetes in 14.2% of adults based on recent government health survey data. 

India carries 27% of the global tuberculosis burden, underlining the ongoing importance of infectious disease diagnostics alongside chronic disease testing. 

Thus, the rising prevalence of both chronic NCDs and persistent infectious diseases worldwide is increasing reliance on IVD tools for effective healthcare delivery, early diagnosis, and disease management.     

In-Vitro Diagnostics Market Analysis Based on Segmental Evaluation:

• Based on product, the In-vitro Diagnostics market is classified into reagents and kits, instruments, and software and services. The reagents and kits segment held the largest In-vitro Diagnostic market share in 2025. Reagents and kits dominate due to recurring demand in routine testing, immunoassays, molecular diagnostics, and high-volume laboratory workflows, ensuring accuracy and timely disease detection.
• By technology, the in-vitro diagnostics market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, microbiology, blood gas analyzers, coagulation and hemostasis, hematology, urinalysis, glucose monitoring, and other technologies. The Immunoassay/Immunochemistry segment held the largest in-vitro diagnostics market share in 2025. Immunoassays lead because of their high specificity and versatility, widely used for detecting infectious diseases, hormones, cancer markers, and chronic condition biomarkers globally.
• In terms of application, the in-vitro diagnostics market is divided into Infectious disease, diabetes, oncology, cardiology, genetic diseases, nephrology, blood grouping and testing, allergy diagnostics, gastrointestinal diseases, immune system disorders, and other applications. The infectious disease segment held the largest in vitro diagnostics market share in 2025. Infectious disease testing dominates, driven by the ongoing need to detect HIV, tuberculosis, hepatitis, and emerging pathogens, enabling early diagnosis and containment.
• By usability, the in-vitro diagnostics market is bifurcated into disposable devices and reusable equipment. Disposable devices are growing fastest due to convenience, reduced contamination risk, and increasing adoption in point-of-care and home-based rapid diagnostic testing.
• By site of testing, the in-vitro diagnostics market is divided into laboratory tests and point-of-care tests. The laboratory tests segment made up a large part of the market in 2025. Laboratory tests dominate as centralized labs handle high sample volumes, equipped with advanced instruments and trained personnel for accurate and comprehensive diagnostics.   
• By specimen, the in-vitro diagnostics market is segmented into blood, serum and plasma, saliva specimens, urine specimens, and Other Specimen. Blood specimens lead as the most common sample type for routine testing, including clinical chemistry, hematology, immunoassays, and molecular diagnostics. 
• By end user, the in-vitro diagnostics market is segmented into hospitals, clinical laboratories, pharmaceutical and biopharmaceutical companies, home care, and other end users. Clinical laboratories dominate due to high-volume testing capabilities, access to sophisticated equipment, and specialization in a wide range of diagnostic assays.

The geographical scope of the in-vitro diagnostics market report includes an assessment of market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. North America dominated with the largest In-vitro Diagnostic market share in 2024. The US leads the market in North America due to advanced healthcare infrastructure, high adoption of innovative diagnostics, strong R&D investments, widespread preventive health programs, and extensive use of molecular, immunoassay, and point-of-care testing, driving early disease detection and chronic condition management across hospitals and laboratories.

Abbott, F. Hoffmann-La Roche Ltd, Danaher Corp, Siemens AG, Becton Dickinson and Co, Thermo Fisher Scientific Inc., MiLab Scientific, ANGEL BIOTECH, Microhaem Scientifics, and Sysmex Corp. are among the leading companies profiled in the in-vitro diagnostics market report.

Geographically, the market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).